Insider Trading & Ownership of Timothy P. Clackson

Location
Cambridge, MA
Summary
The estimated net worth of Timothy P. Clackson is at least $214,649 dollars as of 24 Jul 2025. Timothy P. Clackson is the President and CEO, Director of Theseus Pharmaceuticals, Inc. and owns shares of Theseus Pharmaceuticals, Inc. stock worth about $139.2K. Timothy P. Clackson is the 10%+ Owner of Xilio Therapeutics, Inc. and owns shares of Xilio Therapeutics, Inc. (XLO) stock worth about $75.5K.
Signature
/s/ Robert Yang, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Timothy P. Clackson and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • Timothy P. Clackson has 4 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $214,649.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Theseus Pharmaceuticals, Inc. ($139,156).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Timothy P. Clackson

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
THRX Theseus Pharmaceuticals, Inc. President and CEO, Director $139,156 01 Mar 2023
XLO Xilio Therapeutics, Inc. 10%+ Owner $75,493 21 Oct 2021
ELEV Elevation Oncology, Inc. Director $0 23 Jul 2025
FMTX Forma Therapeutics Holdings, Inc. Director 14 Oct 2022

Insider Transactions Reported by Timothy P. Clackson:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .